Drug ID:Drug87
Drug Name:LTB4
CID:5280492
DrugBank ID:DB12961
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NULL
Molecular Formula:C20H32O4
Molecular Weight:336.5 g/mol
Isomeric SMILES:CCCCC/C=C\\C[C@H](/C=C/C=C/C=C\\[C@H](CCCC(=O)O)O)O
Synonyms:LEUKOTRIENE B4; 71160-24-2; 5,12-Hete; (5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoic acid; 5S,12R-diHETE; UNII-1HGW4DR56D; 1HGW4DR56D; 5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid; CHEBI:15647; LEUKOTRIENE B4 [MI]
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt726 5280492 Leukotriene B4 59 ACTA2 Homo sapiens (human) 27697457 Leukotriene B4 results in increased expression of ACTA2 protein
dt727 5280492 Leukotriene B4 59 ACTA2 Mus musculus (house mouse) 30818366 Leukotriene B4 results in increased expression of ACTA2 mRNA
dt728 5280492 Leukotriene B4 196 AHR Rattus norvegicus (Norway rat) 28487374 AHR mRNA promotes the reaction [tetrachlorodibenzodioxin results in increased chemical synthesis of leukotriene B4]
dt729 5280492 Leukotriene B4 207 AKT1 Homo sapiens (human) 23747687 Leukotriene B4 inhibits the reaction [isoliquiritigenin results in decreased activity of AKT1 protein]
dt730 5280492 Leukotriene B4 240 ALOX5 Homo sapiens (human) 15501964 ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundance of leukotriene b4]|zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundanc
dt731 5280492 Leukotriene B4 240 ALOX5 Homo sapiens (human) 18096136 Quercetin 3-O-glucuronide inhibits the reaction [ALOX5 protein results in increased chemical synthesis of leukotriene b4]|quercetin 3'-sulfate inhibits the reaction [ALOX5 protein results in increased chemical synthesis of leukotriene b4]|luteolin inhibit
dt732 5280492 Leukotriene B4 240 ALOX5 Homo sapiens (human) 11325678 ALOX5 protein results in increased secretion of leukotriene B4
dt733 5280492 Leukotriene B4 240 ALOX5 Homo sapiens (human) 9609743 Zileuton inhibits the reaction [ALOX5 protein results in increased susceptibility to [histamine results in increased abundance of leukotriene B4]]|ALOX5 protein results in increased susceptibility to [histamine results in increased abundance of leukotrien
dt734 5280492 Leukotriene B4 240 ALOX5 Homo sapiens (human) 2849922 [tenidap results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of leukotriene b4|[masoprocol results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of leukotriene B4|[RS 43179
dt735 5280492 Leukotriene B4 240 ALOX5 Homo sapiens (human) 10491155 Resveratrol inhibits the reaction [[hydrogen peroxide results in increased activity of ALOX5 protein] which results in increased chemical synthesis of leukotriene b4]|[hydrogen peroxide results in increased activity of ALOX5 protein] which results in incr

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT04985968 The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis PHASE3 TERMINATED InDex Pharmaceuticals Ulcerative Colitis DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… Details
NCT06681181 A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants PHASE1 RECRUITING GlaxoSmithKline Colitis, Ulcerative DRUG: GSK4528287|DRUG: Placebo Details
NCT05992142 ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA PHASE4 COMPLETED Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW Ulcerative Colitis DRUG: 5-ASA Details
NCT00787202 A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. PHASE2 COMPLETED Pfizer Ulcerative Colitis DRUG: CP- 690 550|DRUG: CP- 690 550|DRUG: CP- 690… Details
NCT06321887 EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD PHASE3 RECRUITING Liverpool University Hospitals NHS Foundation Trust Inflammatory Bowel Disease|Iron Deficiency Anemia DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… Details
NCT00207688 A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients None COMPLETED Janssen Research & Development, LLC Ulcerative Colitis DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… Details
NCT04677179 A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) PHASE2 TERMINATED Nektar Therapeutics Colitis, Ulcerative DRUG: LY3471851|DRUG: Placebo Details
NCT02958865 Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis PHASE2 COMPLETED Pfizer Ulcerative Colitis DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… Details
NCT03943550 Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) PHASE1 TERMINATED Hoffmann-La Roche Ulcerative Colitis DRUG: RO7049665|DRUG: Placebo Details
NCT02840721 Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. PHASE2 COMPLETED Telavant, Inc. Colitis, Ulcerative DRUG: PF-06480605 Details
NCT04133194 Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis PHASE4 RECRUITING Flemming Bendtsen Ulcerative Colitis DRUG: Mesalazine|DRUG: Mesalazine Details
NCT01465763 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis PHASE3 COMPLETED Pfizer Ulcerative Colitis DRUG: tofacitinib|DRUG: Placebo Details
NCT06636656 A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis PHASE2 RECRUITING Boehringer Ingelheim Ulcerative Colitis DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… Details
NCT04996797 A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) PHASE2 ACTIVE_NOT_RECRUITING Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Ulcerative Colitis DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… Details
NCT01458951 A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis PHASE3 COMPLETED Pfizer Ulcerative Colitis DRUG: tofacitinib|DRUG: Placebo Details
NCT04499495 Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea None COMPLETED Ferring Pharmaceuticals Ulcerative Colitis OTHER: PENTASA (mesalamine/ 5-Aminosalicylic acid… Details
NCT01959282 A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis PHASE2 COMPLETED Janssen Research & Development, LLC Colitis, Ulcerative DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… Details
NCT02318667 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). PHASE4 COMPLETED Merck Sharp & Dohme LLC Colitis, Ulcerative BIOLOGICAL: Golimumab Details
NCT00317356 A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis PHASE2 TERMINATED Otsuka Pharmaceutical Co., Ltd. Colitis, Ulcerative DRUG: OPC-6535(Tetomilast) Details
NCT01470612 Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis PHASE3 COMPLETED Pfizer Ulcerative Colitis DRUG: CP-690,550|DRUG: CP-690,550 Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S01 Anti-inflammatory inflammatory 5-Aminosalicylates (5-ASAs); corticosteroids Crohn's disease and ulcerative colitis are the two main com… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations